Dicerna™ to Present at Two Upcoming Investor Conferences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)…
Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)…
NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications,…
The FDA granted the approval of Jynneos for the prevention of monkeypox disease, to Bavarian Nordic A/S, and it granted the application Priority Review, it said Tuesday in a press release.
Belgian Sequana Medical has enrolled the first patient in the North American pivotal study of the alfapump for the treatment of recurrent and refractory ascites due to liver cirrhosis.
FSD Pharma, World-Class Extractions inc have formed a Joint Venture to develop, manage and operate cannabis extraction and processing center at FSD Pharma Facility in Cobourg, Ontario.
Incyte has treated first vitiligo patient in its phase 3 clinical trial testing ruxolitinib cream as a monotherapy for older patients older than 12.
Enanta’s study has met its primary endpoint, as ALT reduction at week 12, was met in the 2.5mg dosing group in testing its lead FXR agonist, EDP-305 for treatment of NASH, also meeting key secondary endpoint, reduction in liver fat content as measured by MRI-PDFF at week 12, in the 2.5mg dosing group.
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
CINCINNATI–(BUSINESS WIRE)–Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2019 financial results after…
HAMILTON, Ontario–(BUSINESS WIRE)–#ABI–VoxNeuro is excited to announce that the company will receive up to CA$249,000 in research and development funding…